Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT06557902
PHASE1

Safety, Tolerability and Pharmacokinetics of Lumateperone in Pediatric Patients With Autism Spectrum Disorder

Sponsor: Intra-Cellular Therapies, Inc.

View on ClinicalTrials.gov

Summary

Study ITI-007-035 is a Phase 1b, multicenter, open-label study to evaluate the safety, tolerability, and PK of lumateperone for pediatric patients with Autism Spectrum Disorder.

Official title: An Open-label, Multiple-dose Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Lumateperone in Pediatric Patients, Ages 5 to Less Than 13 Years, Diagnosed With Autism Spectrum Disorder

Key Details

Gender

All

Age Range

5 Years - 12 Years

Study Type

INTERVENTIONAL

Enrollment

26

Start Date

2024-05-10

Completion Date

2026-07-31

Last Updated

2024-08-16

Healthy Volunteers

No

Interventions

DRUG

Lumateperone 10.5 mg capsule

Lumateperone 10.5 mg capsule, oral administration

DRUG

Lumateperone 21 mg capsule

Lumateperone 21 mg capsule, oral administration

DRUG

Lumateperone 5 mg ODT

Lumateperone 5 mg ODT, oral administration

DRUG

Lumateperone 10.5 mg ODT

Lumateperone 10.5 mg ODT, oral administration

DRUG

Lumateperone 15.5 mg ODT

Lumateperone 5 mg ODT + 10.5 mg ODT, oral administration

DRUG

Lumateperone 21 mg ODT

Lumateperone 21 mg ODT, oral administration

Locations (8)

Clinical Site 6

Miami, Florida, United States

Clinical Site 7

Orlando, Florida, United States

Clinical Site 1

Atlanta, Georgia, United States

Clinical Site 2

Decatur, Georgia, United States

Clinical Site 3

Savannah, Georgia, United States

Clinical Site 4

Saint Charles, Missouri, United States

Clinical Site 5

Lincoln, Nebraska, United States

Clinical Site 8

Everett, Washington, United States